Drug Profile
Ganciclovir implant - Bausch & Lomb
Alternative Names: VitrasertLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator pSivida
- Developer Bausch & Lomb
- Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Cytomegalovirus infections
Most Recent Events
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals